Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Japan's finance minister Katayama said Bessent told her "very good" during her explanation and did not make the demands reported by the media.
2026-09-04
Japan's finance minister Katayama said Bessent told her "very good" during her explanation and did not make the demands reported by the media.
Back
Other News
2026-09-03
Bank of England Chief Economist Peel: Raising interest rates does not mean "long-term and aggressive" rate hikes.
Bank of England Chief Economist Peel: Raising interest rates does not mean "long-term and aggressive" rate hikes.
2026-09-04
Wu Xiaoying, consulting services lead partner at Ernst & Young Greater China, says new contract wins and backlog at CROs have both shown clear improvement. Some preclinical CROs posted high YoY growth in H1 new orders; clinical CROs are seeing a reco
Wu Xiaoying, consulting services lead partner at Ernst & Young Greater China, says new contract wins and backlog at CROs have both shown clear improvement. Some preclinical CROs posted high YoY growth in H1 new orders; clinical CROs are seeing a recovery in new project volumes and new‑win pricing, indicating a demand rebound. She said if innovative drug R&D spending remains as active as now, this year could see the CRO industry move from order repair toward Profitability repair, though recovery timing will differ across business lines. Wu added AI will widen gaps between CROs: by speeding candidate generation and screening in discovery, AI raises the value of faster, higher‑quality experimental validation—firms that rapidly weed out false leads and advance truly promising molecules will be more likely to secure high‑value projects.
Chat with us
, powered by
LiveChat